作者: Ember, Katherine ; Leblond, Frédéric ; Marple, Eric ; Sheehy, Guillaume ; Blanquez-Yeste, Victor ; Tran, Trang ; Janelle, Félix ; Dallaire, Frédérick ; Urmey, Kirk ; Labidi, Moujahed

SignificanceFor most patients with pituitary adenomas, surgical resection represents a viable therapeutic option, particularly in cases with endocrine symptoms or local mass effects. Diagnostic imaging, including MRI and computed tomography, is employed clinically to plan pituitary adenoma surgery. However, these methods cannot provide surgical guidance information in real time to improve resection rates and reduce risks of damage to normal tissue during tumor debulking.AimHere, we present the development of a handheld Raman spectroscopy system that can be seamlessly integrated with transsphenoidal surgery workflows to allow live discrimination of all normal intracranial anatomical structures, including the pituitary gland, and potentially tissue abnormalities such as adenomas.ApproachA fiber-optic probe was developed with a form factor compatible with endoscopic systems for endonasal surgeries. The instrument was evaluated in an ex vivo experimental protocol designed to assess its ability to distinguish normal intracranial structures. A total of 274 in situ spectroscopic measurements were acquired from six lamb heads, targeting key anatomical structures encountered in surgery. Support vector machine models were developed to classify tissue types based on their spectral signatures.ResultsBinary classification models successfully distinguished the pituitary gland from other tissue structures with a sensitivity and a specificity of 100%. In addition, a four-class predictive model enabled __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__> 95 % accuracy in situ discrimination of four structures of most importance during pituitary adenoma tumor resection, i.e., the pituitary gland, the sella turcica (ST) bone, the optic chiasm, and the ST dura mater.ConclusionsThis work sets the stage for the clinical deployment of Raman spectroscopy as an intraoperative real-time decision support system during transsphenoidal surgery, with future work focused on clinical integration and the generalization of the approach to include the detection of tissue abnormalities, such as pituitary adenomas.

2025-01-24·Journal of Biomedical Optics

Quantitative assessment of the generalizability of a brain tumor Raman spectroscopy machine learning model to various tumor types including astrocytoma and oligodendroglioma

Article

作者: Le Moël, Alice ; Ember, Katherine ; Dudley, Roy ; Sheehy, Guillaume ; Tavera, Hugo ; Blanquez-Yeste, Victor ; Petrecca, Kevin ; Leblond, Frédéric ; Hadjipanayis, Costas ; Guiot, Marie-Christine ; Dallaire, Frédérick ; Tran, Trang ; Weil, Alexander G

SignificanceMaximal safe resection of brain tumors can be performed by neurosurgeons through the use of accurate and practical guidance tools that provide real-time information during surgery. Current established adjuvant intraoperative technologies include neuronavigation guidance, intraoperative imaging (MRI and ultrasound), and 5-ALA for fluorescence-guided surgery.AimWe have developed intraoperative Raman spectroscopy as a real-time decision support system for neurosurgical guidance in brain tumors. Using a machine learning model, trained on data from a multicenter clinical study involving 67 patients, the device achieved diagnostic accuracies of 91% for glioblastoma, 97% for brain metastases, and 96% for meningiomas. Here, the aim is to assess the generalizability of a predictive model trained with data from this study to other types of brain tumors.ApproachA method was developed to assess the generalizability of the model, quantifying performance for tumors including astrocytoma, oligodendroglioma and ependymoma, pediatric glioblastoma, and classification of glioblastoma data acquired in the presence of 5-ALA induced fluorescence. Statistical analyses were conducted to assess the impact of vibrational bands beyond contributors identified in our previous research.ResultsA machine learning brain tumor detection model showed a positive predictive value (PPV) of 70% for astrocytoma, 74% for oligodendroglioma, and 100% for ependymoma. Furthermore, the PPV was 100% in classifying spectra from a pediatric glioblastoma and 90% for detecting adult glioblastoma labeled with 5-ALA-induced fluorescence. Univariate statistical analyses applied to individual vibrational bands demonstrated that the inclusion of Raman biomarkers unexploited to date had the potential to improve detectability, setting the stage for future advances.ConclusionsDeveloping predictive models relying on the inelastic scattering contrast from a wider pool of Raman bands may improve detection accuracy for astrocytoma and oligodendroglioma. To do so, larger tumor datasets and a higher Raman photon signal-to-noise ratio may be required.

2024-09-01·Molecular Therapy: Oncology

Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer

Article

作者: Geoffroy, Karen ; Leclerc-Desaulniers, Kim ; Mullins-Dansereau, Victor ; Bourgeois-Daigneault, Marie-Claude ; Viens, Mélissa

Therapy-resistant ovarian cancers have a poor prognosis and novel effective treatment options are urgently needed. In this study, we evaluated the therapeutic efficacy of the oncolytic vesicular stomatitis virus (VSV) against a panel of patient-derived ovarian cancer cell lines of all epithelial subtypes. Notably, we found that most of the cell lines were sensitive to VSV virotherapy. With the objective of improving treatment efficacy for the oncolytic virus-resistant cell lines, we tested various combinations with ovarian cancer standard of care drugs: olaparib, carboplatin, paclitaxel, doxorubicin, cyclophosphamide, and gemcitabine. While none of these combinations revealed to be beneficial, further experiments demonstrated that the antiviral interferon pathway was functional in VSV-resistant cell lines. Given that interferons signal through Janus kinase (JAK)-STAT to mediate their antiviral function, we tested combinations of oncolytic VSV with clinically relevant JAK inhibitors. Our results show that combining VSV with various JAK inhibitors, including ruxolitinib, enhances VSV virotherapy and treatment efficacy. Altogether, we show that VSV, either as a stand-alone treatment or in combination with JAK inhibitors provides an effective therapeutic option for ovarian cancer patients.

项与 Institut Du Cancer De Montreal 相关的新闻（医药）

2013-12-19

·BioSpace

AmorChem l.p.'s KNOCK-OUT Event: We Have A Champion!

Montreal, October 2, 2013. The five Contenders of the first AmorChem KNOCK-OUT Event valiantly climbed into the ring today at BioContact to duke it out against a panel of Heavyweight Champions for a chance to win a coveted $500,000 financing from AmorChem. Earlier in the summer, AmorChem, the innovative Quebec-based venture capital seed fund, launched a province-wide call for proposals to participate in its KNOCK-OUT Event. All the Contenders displayed remarkable courage and agility in the ring, yet only one could stand victorious. It is with great pleasure that AmorChem announces the winner of the 2013 KNOCK-OUT Event: Dr. John Stagg “Targeting CD73 with small molecules in oncology” Institut du cancer de Montréal, Centre de recherche du Centre Hospitalier de l’Université de Montréal and Faculty of Pharmacy, Université de Montréal “This first KNOCK-OUT Event has been quite an adventure and we are very pleased with the outcome of the battle in the ring today. The Heavyweights had a tough job and we are very enthusiastic about their selection,” comments Inès Holzbaur, General Partner at AmorChem. “We would like to thank the Contenders for rolling with the punches, our Heavyweights for bringing their individual expertise into the ring today and Christopher Hall for successfully keeping everyone battling without the rule.” “Our hopes and objectives have been well surpassed for this Event,” says Elizabeth Douville, General Partner at AmorChem. “We created this Event to increase the Quebec research community’s awareness of AmorChem and reach out to researchers who may not have been aware of the possibility of commercialising aspects of their work. This Event definitely reached those goals.” The final bell has rung; AmorChem now looks forward to working with Dr Stagg. The AmorChem KNOCK OUT Event is proudly sponsored by ROBIC, LLP. ABOUT AMORCHEM AmorChem L.P. ( ) is a venture capital fund located in Montreal focused on investing in promising life science projects originating from Quebec-based universities and research centres. The principal limited partners of this fund are Investissement-Québec, FIER Partenaires, Fonds de solidarité FTQ and Merck & Co. This fund is the latest addition to the GeneChem portfolio of funds, a fund manager in existence since 1997. AmorChem’s innovative business model involves financing research-stage projects to enable them to reach pre-clinical proof-of-concept (“POC”) in a semi-virtual mode within 18-24 months. The fund seeks to generate returns through a two-pronged exit strategy: sell projects having reached POC to large biotechnology or pharmaceutical companies; or bundle them into new spin-out companies. AmorChem using external resources will manage the projects. To that effect, AmorChem has established a strategic partnership with the Biotechnology Research Institute in order to access its R&D platforms. In addition, to enabling projects requiring small molecules as tools or drug leads, AmorChem has founded NuChem Therapeutics Inc., a medicinal chemistry contract-research company. Media Contact for AmorChem Mélanie Larouche T 418 521 3771 E melanie.larouche@citoyenoptimum.com .ABOUT ROBIC Founded in 1892, ROBIC, LLP is an internationally renowned firm of lawyers, patent and trade-mark agents specialized in Intellectual Property and Business Law. Headquartered in Montreal, ROBIC is a Canadian firm with more than 175 people including 23 partners and 45 professionals. We provide dynamic and entrepreneurial assistance and representation to clients in executing business transactions in addition to managing, protecting, enforcing and commercialising their intellectual capital. ABOUT BIOCONTACT BioContact Quebec 2013: The 19th edition will take place on October 2nd and 3rd 2013, at the Château Laurier in Québec City. Representatives from over 24 biopharmaceutical companies from Canada, the United States and Europe will be attending. Help employers find you! Check out all the jobs and post your resume.

小分子药物合作

100 项与 Institut Du Cancer De Montreal 相关的药物交易

登录后查看更多信息

100 项与 Institut Du Cancer De Montreal 相关的转化医学

登录后查看更多信息